| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | R3; CD1A; R3G1 |
| Entrez GeneID | 912 |
| clone | 3A6G3 |
| WB Predicted band size | 37.7kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD1D (AA: extra 20-301) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是与CD1D抗体相关的3篇文献及其摘要概述：
---
1. **文献名称**：*CD1D-mediated antigen presentation by NKT cells requires endosomal localization and autoantigen trafficking*
**作者**：Brigl M, Brenner MB
**年份**：2005
**摘要**：研究揭示了CD1D分子在自然杀伤T细胞(NKT细胞)激活中的作用，发现其依赖内体定位和自身抗原运输。通过抗CD1D抗体的阻断实验，证实CD1D在脂质抗原呈递中的必要性。
---
2. **文献名称**：*Structural features of CD1D required for its antigen presentation function in NKT cell activation*
**作者**：Bai L et al.
**年份**：2013
**摘要**：通过X射线晶体学分析CD1D分子的结构，发现其脂质结合域的特定区域对NKT细胞受体识别至关重要。抗CD1D抗体被用于验证关键表位，为靶向治疗提供结构学依据。
---
3. **文献名称**：*CD1D-restricted T cell responses in tumor immunity: implications for antibody-based immunotherapy*
**作者**：Robertson FC et al.
**年份**：2020
**摘要**：探讨CD1D限制性T细胞在抗肿瘤免疫中的作用，并评估抗CD1D抗体在增强免疫检查点疗法中的潜力。实验显示抗体可促进肿瘤微环境中NKT细胞的活化。
---
4. **文献名称**：*Characterization of monoclonal antibodies specific for human CD1D isoforms*
**作者**：Exley MA et al.
**年份**：1999
**摘要**：早期研究报道了针对人CD1D异构体的单克隆抗体的开发与功能验证，确认其特异性结合能力及在流式细胞术和免疫组化中的应用价值。
---
这些文献覆盖了CD1D的免疫功能、结构机制及抗体开发，部分研究直接利用抗CD1D抗体进行功能验证。如需具体文献链接或补充信息，可进一步提供方向。
CD1d antibodies are essential tools for studying the function of CD1d, a non-classical major histocompatibility complex (MHC) class I-like molecule. CD1d is primarily expressed on antigen-presenting cells, such as dendritic cells, B cells, and intestinal epithelial cells. Unlike MHC molecules that present peptide antigens, CD1d binds lipid-based antigens and presents them to invariant natural killer T (iNKT) cells, a specialized T cell subset bridging innate and adaptive immunity. This interaction activates iNKT cells, triggering rapid cytokine production and modulating immune responses against infections, tumors, and autoimmune diseases.
CD1d antibodies are used to detect CD1d expression in tissues, block CD1d-antigen presentation, or modulate iNKT cell activity in experimental models. They have been instrumental in elucidating CD1d's role in lipid metabolism, mucosal immunity, and diseases like inflammatory bowel disease, multiple sclerosis, and cancer. Therapeutic applications are also emerging; anti-CD1d antibodies are being explored to suppress harmful immune reactions in autoimmunity or enhance antitumor responses. Additionally, CD1d-targeting antibody-drug conjugates are under investigation for precision cancer therapies. However, CD1d's conservation across species and its complex ligand-binding properties pose challenges in antibody development. Recent advances in structural biology and hybridoma technology have improved antibody specificity, aiding both basic research and clinical translation. Ongoing clinical trials (e.g., NCT04887298) highlight the growing interest in CD1d-based immunotherapies.
×
